In this Issue
- We explore psychedelics-related lobbying activity at the federal level in Q3’24, which saw a significant increase in such efforts
- Psychoplastogens a ‘primary focal point’ of depression trials last year
- NJ Psilocybin Bill Appears Dead
- FDA moves to restrict Amanita muscaria
- DEA increases DMT production quota
- and more…
***
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue